Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5456MR)

This product GTTS-WQ5456MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5456MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7385MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ12547MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ15779MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11704MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ798MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ11670MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ4079MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ15794MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW